GainersToday.com
GainersToday.com, Tracking Stock Market Picks
Enter Symbol:
 
Horizon Pharma Inc (HZNP) [hlAlert]

Rating:
Mkt Outperform
HZNP
up 267.30 %

Horizon Pharma Inc (HZNP) rated Mkt Outperform by JMP Securities

Posted on: Wednesday,  Sep 9, 2015  10:25 AM ET by JMP Securities

JMP Securities rated Mkt Outperform Horizon Pharma Inc (NASDAQ: HZNP) on 09/09/2015. Previously JMP Securities rated Mkt Outperform Horizon Pharma Inc (NASDAQ: HZNP)
on 09/07/2011., when the stock price was $8.35. Since then, Horizon Pharma Inc has gained 267.31% as of 01/19/2016's recent price of $30.67.
If you would have followed the previous JMP Securities's recommendation on HZNP, you would have gained 267.3% of your investment in 1595 days.

Horizon Pharma, Inc. (Horizon) is a biopharmaceutical company that develops and commercializes medicines to target unmet therapeutic needs in arthritis, pain and inflammatory diseases. On April 23, 2011, the United States Food and Drug Administration, approved DUEXIS (formerly HZT-501), a tablet formulation containing a fixed-dose combination of ibuprofen and famotidine in a single pill. The Company?s other product, LODOTRA (NP-01), is a programmed release formulation of low-dose prednisone that is marketed in Europe by the Company?s distribution partner, Mundipharma International Corporation Limited (Mundipharma). As of December 31, 2010, Horizon completed multiple Phase III clinical trials of LODOTRA. In addition to these product candidates, the Company has a pipeline of earlier-stage product candidates to treat pain-related diseases and chronic inflammation.

MP Securities' equity research department provides institutional clients with comprehensive industry knowledge, unique insight and actionable information. JMP's senior research analysts are charged with developing proprietary investment themes, anticipating secular and cyclical changes and producing action-oriented reports. JMP follows companies in six industries that exhibit above-average long-term growth characteristics — Technology, Healthcare, Consumer, Real Estate, Financial Services and Business Services — and produces specialized equity research that enables investors to understand and invest in complicated growth stocks profitably.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
9/9/2015 10:25 AM Buy
None
29.05
as of 8/27/2015
1 Week down  -7.28 %
1 Month down  -10.50 %
3 Months up  7.99 %
1 YTD up  302.49 %
Previous Recommendations
Date/Time (ET)SymbolRatingTermPrice (*)Target
3/20/2014 9:25 AM Buy
None
16.81 22.00
1/30/2014 9:25 AM Buy
None
9.90 16.00
9/7/2011 11:25 AM Buy
None
8.35 16.00

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy